GlassScriptPhysician profile
Kathrine C Mobisson
NPI 1124102223
$3,960.02
in general payments reported to CMS, 2019-2025
25 companies · $701 in 2025
The $701 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $316 · 2021: $617 · 2022: $464 · 2023: $503 · 2024: $754 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $473.95 | 2022-2025 | Azstarys |
| Lundbeck LLC | $457.60 | 2019-2024 | Rexulti |
| Abbvie INC. | $319.32 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $310.01 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $289.38 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $242.89 | 2019-2024 | Jornay Pm |
| Validus Pharmaceuticals LLC | $235.75 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.05 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $202.78 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $199.68 | 2021-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $150.02 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Tris Pharma INC | $101.52 | 2019-2025 | Dyanavel Xr |
| Allergan, INC. | $101.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $93.84 | 2019 | |
| Alkermes, INC. | $92.71 | 2022-2025 | Aristada, Lybalvi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $72.66 | 2024 | |
| Adlon Therapeutics L.P. | $69.75 | 2020-2021 | |
| Bausch Health US, LLC | $65.61 | 2020-2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $65.44 | 2019-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $58.21 | 2025 | Jornay Pm |
| Shire North American Group INC | $49.61 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.24 | 2019-2024 | Relexxii |
| Neos Therapeutics, LP | $29.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.70 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathrine Mobisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.